177 related articles for article (PubMed ID: 27166975)
21. [Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2].
Spasov AA; Chepljaeva NI
Biomed Khim; 2015; 61(4):488-96. PubMed ID: 26350740
[TBL] [Abstract][Full Text] [Related]
22. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
23. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
[TBL] [Abstract][Full Text] [Related]
24. An updated review on cancer risk associated with incretin mimetics and enhancers.
Tseng CH; Lee KY; Tseng FH
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
[TBL] [Abstract][Full Text] [Related]
25. [Rationale supporting basal insulin-incretin combined therapies in type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Liege; 2013 Nov; 68(11):562-8. PubMed ID: 24396969
[TBL] [Abstract][Full Text] [Related]
26. The future of incretin-based therapy: novel avenues--novel targets.
Ahrén B
Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():158-66. PubMed ID: 21824270
[TBL] [Abstract][Full Text] [Related]
27. Incretin effect: GLP-1, GIP, DPP4.
Kazafeos K
Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S32-6. PubMed ID: 21864749
[TBL] [Abstract][Full Text] [Related]
28. Investigation of gene-diet interactions in the incretin system and risk of type 2 diabetes: the EPIC-InterAct study.
InterAct Consortium
Diabetologia; 2016 Dec; 59(12):2613-2621. PubMed ID: 27623947
[TBL] [Abstract][Full Text] [Related]
29. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
Drab SR
Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in incretin-based therapies.
Russell-Jones D; Gough S
Clin Endocrinol (Oxf); 2012 Oct; 77(4):489-99. PubMed ID: 22804841
[TBL] [Abstract][Full Text] [Related]
31. Physiology and pathophysiology of incretins in the kidney.
von Websky K; Reichetzeder C; Hocher B
Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
[TBL] [Abstract][Full Text] [Related]
32. [Incretin and incretin-based therapies].
Harada N; Inagaki N
Nihon Rinsho; 2010 May; 68(5):931-42. PubMed ID: 20446595
[TBL] [Abstract][Full Text] [Related]
33. Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin.
Zimdahl H; Ittrich C; Graefe-Mody U; Boehm BO; Mark M; Woerle HJ; Dugi KA
Diabetologia; 2014 Sep; 57(9):1869-75. PubMed ID: 24906949
[TBL] [Abstract][Full Text] [Related]
34. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
35. [Pathophysiological background for incretin therapy: is it capable of more than we think?].
Haluzík M; Urbanová M; Haluzíková D; Trachta P
Vnitr Lek; 2011 Nov; 57(11):897-902. PubMed ID: 22165692
[TBL] [Abstract][Full Text] [Related]
36. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
Triplitt C; Wright A; Chiquette E
Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
[TBL] [Abstract][Full Text] [Related]
37. beta-cell failure in diabetes and preservation by clinical treatment.
Wajchenberg BL
Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
[TBL] [Abstract][Full Text] [Related]
38. Integrating incretin-based therapy into type 2 diabetes management.
Brunton SA
J Fam Pract; 2013 Jun; 62(6 Suppl CME):S1-8. PubMed ID: 23828807
[No Abstract] [Full Text] [Related]
39. Incretin-based therapies: review of current clinical trial data.
Peters A
Am J Med; 2010 Mar; 123(3 Suppl):S28-37. PubMed ID: 20206729
[TBL] [Abstract][Full Text] [Related]
40. [How I TREAT ... THE ROLE OF DPP-4 INHIBITORS (GLIPTINS) IN THE TREATMENT OF TYPE 2 DIABETES].
Scheen AJ
Rev Med Liege; 2015 Dec; 70(12):593-9. PubMed ID: 26867302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]